Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease‐related symptoms in patients with myelofibrosis (MF). However, no clear survival benefit has been demonstrated, which may in part reflect suboptimal drug expo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Autores principales: Pugliese, Novella, Giordano, Claudia, Nappi, Davide, Luciano, Luigiana, Cerchione, Claudio, Annunziata, Mario, Casale, Beniamino, Crisà, Elena, Villa, Maria Rosaria, Pezzullo, Luca, Iovine, Maria, Picardi, Marco, Grimaldi, Francesco, Pane, Fabrizio, Martinelli, Vincenzo
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6558489/
https://ncbi.nlm.nih.gov/pubmed/30997748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2147
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares